We explored adeno-associated viral vector (AAV) 
Introduction
Congenital FVII deficiency (CFVIID) is the most common autosomal recessive bleeding disorder, with an estimated prevalence of 1:500,000 in the West, but four times higher in parts of the world where consanguinity is common.
1 CFVIID is caused by mutations in the coagulation factor VII (FVII) gene (13q34) resulting in low or undetectable plasma FVII levels. Factor VII is a vitamin K dependent serine protease that is synthesized in the liver. The interaction of FVII with tissue factor (TF) generates the serine protease FVIIa, which is pivotal for activation of coagulation at the site of vascular injury. Deficiency of FVII results in a bleeding diathesis that is heterogeneous but severe or lethal in at least 20% of patients with a homozygous or compound heterozygous genotype.. Infants with severe factor VII deficiency (Factor VII 0%) invariably develop fatal intracranial haemorrhage within hours or days of birth. If undiagnosed and untreated this is fatal.
Subjects with slightly less severe reduction of factor VII level to 1% or higher may escape this complication and present later with joint bleeding, epistaxis or some other haemorrhagic manifestation. 2, 3 Currently, recombinant activated FVII (rFVIIa) is the treatment of choice in the West.
However, the very short half-life (~2 hours) necessitates frequent intravenous (IV) infusions, more than is required for haemophilia A or B or any other coagulation factor deficiency. The annual cost of treating bleeding episodes with rFVIIa is approximately £1 million/child in the U.K, which makes prophylaxis untenable on economic grounds for all but the wealthiest countries. To reduce the constant risk of life threatening haemorrhage,
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From many children with CFVIID undergo liver transplantation, despite the significant morbidity and mortality of this procedure. 4 The situation is worse in the developing world, where treatment of bleeding episodes is limited to plasma derived products, which are in scarce supply or contaminated with blood-borne pathogens. 2, 3, 5 CFVIID is a good model for perinatal gene transfer because its clinical manifestations are attributable to the lack of a single gene product (FVII) that circulates in minute amounts in the plasma (500 ng/ml). Unlike other congenital liver disorders, the therapeutic goal for CFVIID is modest as an increase in the circulating levels of FVII to >5% of normal will be sufficient to ameliorate the bleeding diathesis. 6 Response to factor replacement therapy in CFVIID is not influenced by additional factors such as substrate flux and metabolic state, a substantial advantage for a proof-of-concept study over other liver gene therapy targets. Notably, FVII is structurally and functionally related to human FIX (hFIX), a molecule that is a focus of successful gene replacement strategies. [7] [8] [9] [10] [11] [12] In contrast to haemophilia A and B, gene therapy for CFVIID remains relatively unexplored. This is in part because effective gene therapy for CFVIID would require For personal use only. on October 4, 2017. by guest www.bloodjournal.org From deficiency. [13] [14] [15] [16] [17] [18] In addition to their excellent safety profile, the most attractive attribute of these vectors is their ability to mediate persistent therapeutic transgene expression following a single administration of vector in a variety of animal models. 7, 8, [19] [20] [21] [22] Emerging results from clinical trials suggest that long-term persistent expression of a transgene is indeed achievable in humans. 17, 23, 24 We and others have recently shown that the potency of rAAV-mediated gene transfer can be further improved by the use of selfcomplementary vectors (scAAV) in animals and humans, which further enhances the safety profile of AAV vectors as well as easing the burden of vector production. 9, [25] [26] [27] While significant progress has been made with the use of these vectors in adults, their evaluation in the preclinical setting for gene transfer in the perinatal period to moderate a disease requires further investigation.
In this study we used CFVIID as a model to establish the potential for perinatal AAV gene transfer in preventing death and long-term disease pathology. Our results show that gene transfer in early life using an AAV vector in mice was protective from diseaseassociated mortality. We have also shown that prenatal gene transfer using established techniques and scAAV vectors confers a therapeutic level of transgene expression without toxicity in young rhesus monkeys.
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Methods

Vector Design and Production
The murine and human FVII cDNAs were cloned into our previously described expression cassette downstream of the LP1 liver specific promoter and upstream of the SV40 poly-A signal ( Figure 1A and 2A) . 25 The coding region of scAAV-LP1-hFVII-wt is based on human FVII cDNA (NM_019616.2) with its 5' and 3' untranslated regions removed in order to meet the packaging constraints of a self-complementary AAV vector.
A codon-optimised version of this shorter form of hFVII cDNA was synthesised using codons most frequently found in highly expressed eukaryotic genes and inserted into a scAAV-LP1 backbone to form scAAV-LP1-hFVII-coop.
scAAV stocks were produced as described previously. 28 Briefly, calcium phosphate precipitation was used to transfect 293 cells with an adenoviral helper plasmid, an AAV5 or 8 capsid packaging plasmid, and the AAV-FVII vectors which are based on the AAV2
genome. The harvested crude lysate was purified using an AVB-sepharose chromatography column (AAV8) or a mucin column (AAV5). Virus yield was quantified by quantitative PCR (qPCR) and capsid proteins visualised by Coomassie staining of virus aliquots run on a denaturing acrylamide gel.
Alkaline gel electrophoresis
Purified virus was exposed to DNAse I prior to genomic DNA extraction with SDS and proteinase K. Proviral DNA was isolated, then electrophoresed in non-denaturing or alkaline 1% agarose gel in TBE buffer and visualised using ethidium bromide.
Molecular Analysis
DNA from monkey liver samples was digested using EcoRI or BsrDI (single and double cutters of the viral genome, respectively). The resulting fragments were separated by electrophoresis and transferred to a nitrocellulose membrane. The membrane was then probed with a 408 bp fragment of plasmid scAAV-LP1-hFVII-coop obtained by digestion with PfoI. A standard curve was made by serial dilution of scAAV-LP1-hFVIIcoop, similarly cut. Using these reagents, an immunocapture assay was developed that could detect as little as 3 ng of human FVII in 1 ml of mouse plasma. The lower limit of detection of human FVII in rhesus plasma was 15 ng/ml because of cross reactivity with rhesus FVII.
Transduction of HepG2 cells in vitro
Evaluation of hFVII transgene expression
When comparing expression from wild-type and codon optimised vectors, results were vulnerable to distortion by differences in transduction efficiency of the two virus stocks.
To overcome this, expression levels were normalised against vector genome copy number. qPCR targeting the LP1 promoter (Fw: TGGTGGTGCCTGAAGCTGAG Rv: GGAGACGAGCAGAGGTTGTC). was used to quantify the viral genomes and host genome copies in DNA extracted from liver tissue samples, to determine the number of viral genome copies per liver cell on day 45 FVII expression data as measured by ELISA were normalised by dividing measured FVII by these vector genome copy numbers, giving the FVII expression/vector genome/cell.
Western blotting of FVII was based on dilution of plasma 1/10 in RIPA cell lysis buffer before denaturing acrylamide electrophoresis and subsequent transfer to a PVDF membrane, which was then blocked using 1% BSA in TBS-Tween for 1 hour at room temperature. Antibodies and standards were used as described for the ELISA.
Evaluation of vectors in vivo
All animal procedures were performed in accordance with institutional guidelines under term 165±10 days) AAV vector was administered under ultrasound guidance by the IP route using established protocols. 31 Newborns were delivered by cesarean-section at term (160±2 days gestation), umbilical cord blood samples collected (~15 ml), simian Apgar scores assessed, then infants were placed in incubators post-delivery and nurseryreared. 31 Infant health, food intake, and body weights were recorded daily or weekly (dependent on age) in the nursery according to established protocols. At approximately 3 months postnatal age animals were placed in juvenile housing and weighed regularly.
Blood samples were collected from a peripheral vessel at 1-week then monthly postnatal age for complete blood counts (CBCs), serum chemistry panels, and coagulation profiles Adult macaques received vector at the St. Jude Children's Research Hospital non-human primate facility. Three female macaques, ages 9 -10 years (average weight = 6.8kg) and three male macaques, 3.5 -9 years (average weight = 6.5kg) were used. Vector was administered as a bolus infusion via a saphenous vein as previously described. 11 Blood samples were subsequently collected monthly. At the time of euthanasia, liver and gonadal tissues were collected, as described above.
Antibodies against AAV5, AAV8 and hFVII-coop were assayed by ELISA
Immunocapture plates were coated with the appropriate antigen (AAV8, AAV5 or recombinant hFVII) before incubation with plasma samples. Bound antibody was detected using HRP-conjugated anti-rhesus IgG antibody, visualised using the OPD substrate, reading absorbance at 490 nm. The titre of the antibody is defined arbitrarily as the reciprocal of the dilution whose absorbance is equal to three times the mean background absorbance level, as described previoously. 32 Murine FVII activity levels were analysed using a chromogenic assay (Hyphen BioMed, Neuville-sur-Oise, France) according to the kit instructions.
Results
rAAV-LP1-mFVII mediated gene transfer in a murine model of FVII deficiency
To demonstrate the potential of AAV-mediated FVII expression, a vector encoding murine FVII pseudotyped with AAV8 capsid ( Figure 1A ) was administered as a bolus injection (2x10 13 vg/kg) at day 35 of life into low-expressing FVII mice described previously by Castellino et al. 33 These mice express FVII at 1.96%±0.46 of wild type levels as measured by a chromogenic assay, sufficient for them to survive birth and for several weeks after but not high enough to prevent a range of pathologies including spontaneous haemorrhage.
33
In AAV FVII-treated mice, the plasma mFVII level reached 312%±40% at 11 days after gene transfer and was maintained at this level for the duration of the study (two months)
following gene transfer, as assessed by a chromogenic assay (N=9). In contrast, untransduced low-expressing FVII littermates exhibited stable FVII activity of 1.18±0.61% of normal levels ( Figure 1B ). This difference was highly significant (p<0.0001).
Kaplan-Meier survival curves were plotted for the AAV FVII-treated low-expressing FVII mice and compared using the log-rank test with survival in control animals. As shown in Figure 1C , transduced mice had a significant survival advantage when compared to control mice. After 67 days post administration (100 days post natal), 57%
of untransduced low-FVII mice had died (N=13/23). Post-mortem inspection showed that
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From the deceased untreated low-FVII mice invariably had evidence of intracranial hemorrhage but no bleeding elsewhere including the peritoneal and thoracic cavities. This suggested that CNS bleeding was likely a significant contributing factor to death. Early death or post-mortem evidence of haemorrhage were not observed in FVII-low mice treated with rAAV8-LP1-mFVII vector, with survival of all (N=19/19) mice in this cohort at 67 days post administration (100 days post natal). This survival advantage was highly significant (p<0.0001). The stable mFVII expression and significant survival advantage observed in mice following a single injection of AAV vector justified further exploration of AAVmediated perinatal gene transfer using the CFVIID model.
In vitro evaluation of scAAV-LP1-hFVII constructs
In preparation for evaluation of this strategy in a context relevant to humans, we constructed a self-complementary AAV (scAAV) vector encoding wild-type human FVII (hFVII, Figure 2A ), as murine FVII cannot be activated by primate tissue factor. scAAV vectors are more potent than single stranded AAV but have a limited packaging capacity of ~2.3 kb. To meet the packaging constraints of scAAV, the 5' and 3' untranslated regions of the hFVII cDNA were deleted (scAAV-LP1-hFVII-wt). In a second vector, the shortened wild type hFVII cDNA was replaced with a codon optimised form of the gene (scAAV-LP1-hFVII-coop) in which codon usage had been altered to better reflect the tRNA availability in mammalian cells in a manner described before for human FIX. 9 The 1336 bp wild-type and codon-optimised sequences of FVII cDNA were 84% identical at the nucleotide level and showed 100% identity at the peptide level. Full sequences of Figure 2B ) as under non-denaturing conditions, the viral DNA migrated at a size of ~2.3 kb, while under alkaline conditions its apparent size was ~4.6 kb.
Next, the HepG2 human liver hepatoma cell line was transduced with scAAV-LP1-hFVII-coop, and secreted proteins collected in serum-replacement media X-Vivo 10.
Media harvested from transduced cells had 2.4 fold higher levels of hFVII than media harvested from untransduced HepG2 cells ( Figure 3A) , which as expected naturally secrete low levels of endogenous hFVII.
The biological activity of hFVII secreted from these cells was confirmed using a chromogenic assay. The ratio of FVII protein (as detected by ELISA) to FVII activity was similar for untransduced (0.92) and transduced (0.78) cells. The lower biological activity is probably explained by the lack of supplemental vitamin K in the culture media.
Nevertheless, these data confirm that the codon optimised form of hFVII generated biologically active FVII at levels comparable to those of the wild type coding sequence (p=0.11).
Evaluation of hFVII constructs in mice
Prior to evaluation in nonhuman primates the scAAV-LP1-hFVII constructs were evaluated in wild type mice. A dose of 2.8x10 12 vg/kg of scAAV8-LP1-hFVII-coop or
scAAV8-LP1-hFVII-wt pseudotyped with AAV serotype 8 capsid was injected into the tail vein of two groups of four male mice. As shown in Figure 3B , after correction for viral copies/liver cell, mice transduced with scAAV8-LP1-hFVII-coop expressed FVII (118.5%±40.79) at a level that was 37-fold higher than those transduced with scAAV8-LP1-hFVII-wt (5.1%±0.11) on day 45 after gene transfer.
Northern blot analysis showed similar levels of hFVII mRNA in the liver of the scAAV8-LP1-hFVII-wt and scAAV8-LP1-hFVII-coop cohorts ( Figure 3C ). This finding supports the hypothesis that the observed increased efficiency of FVII expression from the codon optimised gene is due to improved post-transcriptional processing.
Western blot analysis of plasma derived from mice transduced with scAAV8-LP1-hFVIIcoop showed a band at 50 kDa, the expected size of hFVII, thus confirming that full length hFVII was being expressed in mice ( Figure 4D ).
Next, varying doses of scAAV8-LP1-hFVII-coop vector (range: 1x10 9 to 1x10 12 vg/kg) were injected into the tail vein of 6-8 week old male C57Bl/6 mice (N=5-8 animals/cohort). Levels of hFVII circulating in mouse plasma showed a dose dependent response to the vector dose, as quantified by ELISA ( Figure 3E ). Doses of scAAV8-LP1-hFVII-coop as low as 1x10 9 vg/kg were sufficient to mediate hFVII at levels >5% of normal, which are likely to be therapeutic. Administration of 1x10 12 vg/kg resulted in expression of hFVII at 174.7±54.96% of normal without toxicity.
Codon-optimised hFVII is expressed at equivalent levels by male and female adult macaques
Previous work with AAV vectors in mice showed that liver transduction in females was 5-to 13-fold less efficient than in males. 34 Although this relative inefficiency in females can be partially corrected through the use of self-complementing vectors or pre-treatment with bortezomib and testosterone, 34, 35 this is a critical concern for CFVIID, an autosomal recessive condition.
In order to investigate sex-dependent differences in transgene expression in nonhuman primates, three male-female pairs of adult rhesus monkeys were injected with scAAV5-LP1-hFVII-coop. Plasma hFVII levels were measured at varying time points using an immune capture assay that can detect as little as 15 ng/ml of hFVII in normal rhesus monkey plasma ( Figure 4A ). Transgene expression reached peak levels of 15.0%±5.1 and 12.28%±0.68 in male and female macaques respectively prior to declining to steady state level of approximately 7.2%. This pattern of AAV-mediated transgene expression has been described before for AAV vectors encoding human FIX. 25 Transgene expression was maintained at this level for at least 180 days (duration of the study) after gene transfer with no significant difference in average plasma FVII levels between the male and female cohorts.
Viral genome copy numbers were assessed in liver samples by both Southern blot ( Figure   4B ). This assay confirmed that the virus transduced male and female livers with equal
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hFVII is expressed at therapeutic levels in neonatal monkeys after fetal gene transfer.
Three newborn monkeys were delivered uneventfully at term following in-utero gene transfer of scAAV5-LP1-hFVII-coop. They remained healthy during the study period with no evidence of adverse findings. All CBCs and clinical chemistry panels were within normal limits for animals in this age group when compared to historical controls (Tarantal, unpublished data). All coagulation panels were also found to be within normal limits. Body weights at birth and throughout the study period paralleled the normal historical control range.
Levels of circulating hFVII were assessed from frequent blood samples and measured by ELISA. As shown in Figure 5A Approximately one year after fetal gene transfer, the monkeys were re-challenged with scAAV-LP1-hFVII-coop vector, pseudotyped with serotype 8 capsid (scAAV8-LP1-hFVII-coop), in order to evade the humoral immune response against AAV5 during the initial treatment. The vector was administered in ketamine-sedated monkeys as a slow bolus infusion into a peripheral vein at a dose of 4x10 11 vg/kg, and was well tolerated.
Following IV injection of scAAV8-LP1-hFVII-coop plasma hFVII levels increased, with a mean peak of 165%±10.8% at 1 month post-injection ( Figure 5A ). After this initial peak, expression stabilized at approximately 47.3%±27.7% until 3 months post-injection and was still detectable at therapeutic levels until tissue harvest. As before, the decline in expression was not associated with an increase in serum transaminase levels or with the development of inhibitory antibodies against FVII, as assessed by ELISA and a modified Bethesda assay. As expected, IgG antibodies against the AAV8 capsid were detected in plasma samples within 4 weeks of administration of scAAV8-LP1-hFVII-coop ( Figure   5C ).
Analysis of tissues collected for biodistribution studies using a qPCR assay confirmed that the highest concentration of viral genomes was in the liver. Approximately 10-fold lower levels of the FVII provirus were detected in other tissues (see Table 1 ). This biodistribution profile is consistent with prior reports. 11 It is important to note that other studies have shown that a positive PCR finding in gonadal sections does not imply that 
Discussion
Gene therapy is beginning to show promise for the treatment of a variety of monogenic diseases in adults. However, many genetic diseases present with early onset of irreversible organ damage or mortality. To treat these disorders successfully, safe and efficacious gene therapy vectors and treatment protocols are needed. 30, 31 In this study, we improved post-transcriptional processing. This is consistent with our experience with the human FIX and FVIII genes. 42 The reason for the variability in the success of codon optimization is currently unclear but may relate to moderation of translation which could impact protein folding.
We, and others, have previously shown that AAV vectors are more efficient at mediating gene transfer in males compared to females in rodents and canine models.
9, 34, 35, [43] [44] [45] [46] However, in nonhuman primates gene transfer efficiency in males and females has consistently been shown to be equivalent. 30 While the reason for this species-specific difference remains unknown, it is consistent with other variations in the biological processing of AAV vectors in primates compared to other animal models. 25 This observation clearly has significant implications for CFVIID as well as other disorders where females are affected by disease in significant numbers. Our data in nonhuman primates suggests that there is no need to develop different treatment protocols for female patients involving the use of androgens or proteosome inhibitors in order to achieve the same level of gene transfer as in male patients, 25, 35 and emphasizes the importance of choice of species for preclinical studies.
In-utero gene transfer using viral vectors remains a controversial area and prohibited in humans by a variety of regulatory bodies around the world, in part because of a poor understanding of the toxicity associated with this procedure. Our data suggest that ultrasound-guided in-utero administration of AAV vector in the late third trimester in nonhuman primates is feasible and safe for the fetus and the dam. This is consistent with
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other reports from our group and others in large animal models. 11, [29] [30] [31] 47 In-utero gene transfer of human FVII conferred expression at the time of birth and shortly thereafter within the range of values that could offer protection to children with severe CFVIID in the early postnatal period, which is the critical time associated with perinatal death.
However, as in other large animal models rAAV mediated transgene expression declined over time. This decline in the post-natal period is most likely due to loss of episomally retained transgene as shown previously in juvenile mice 48, 49 and by our group in monkeys and sheep. 11, 47 Nevertheless, re-administration of the vector pseudotyped with an antigenically distinct capsid was successful in restoring expression in young rhesus monkeys, which was then maintained at therapeutic levels until the end of the study.
The formation of inhibitory antibodies against therapeutic factors is a major concern in the treatment of the haemophilias, and must be considered in the development of gene therapy vectors. Throughout our study, no inhibitory antibodies against hFVII were detected, corresponding to the low incidence of inhibitor formation in patients receiving FVII infusions, 50 and to our previous data suggesting that early expression of transgenes from the liver can help to confer immunological tolerance. 11, 47 While these data are very encouraging, the potential for species-specific differences in the immune response means that this must be interpreted with caution when beginning to consider the exploration of these techniques in human patients.
In summary, perinatal gene transfer with the AAV vectors used in these studies was found to be safe and efficient, with transgene expression at therapeutic levels in mice and rhesus monkeys. For personal use only. on October 4, 2017. by guest www.bloodjournal.org From
